Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib
OncoPharm
00:00
Adjuvant Pembrolizumab Approval Details
John explains FDA approval of one-year adjuvant pembrolizumab after resection and platinum chemo for stage IB–3A NSCLC, based on Keynote-091.
Play episode from 00:34
Transcript
